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Abstract
We assessed the persistence of hepatitis B surface antigen antibody (anti-HBs) and immune memory in a cohort of 571 teenagers vaccinated
against hepatitis B as infants, 17 years earlier. Vaccinees were followed-up in 2003 and in 2010 (i.e. 10 years and 17 years after primary
vaccination, respectively). When tested in 2003, 199 vaccinees (group A) had anti-HBs <10 mIU/mL and were boosted, 372 (group B) were
not boosted because they had anti-HBs ≥10 mIU/mL (n = 344) or refused booster (n = 28) despite anti-HBs <10 mIU/mL. In 2010, 72.9%
(416/571) of participants had anti-HBs ≥10 mIU/mL (67.3% in group A vs. 75.8% in group B; p 0.03). The geometric mean concentrations
(GMCs) were similar in both groups. Between 2003 and 2010, anti-HBs concentrations in previously boosted individuals markedly declined
with GMC dropping from 486 to 27.7 mIU/mL (p <0.001). Fifteen vaccinees showed a marked increase of antibody, possibly due to natural
booster. In 2010, 96 individuals (37 of group A and 59 of group B) with anti-HBs <10 mIU/mL were boosted; all vaccinees of the former group
and all but two of the latter had an anamnestic response. Post-booster GMC was higher in group B (895.6 vs. 492.2 mIU/mL; p 0.039). This
ﬁnding shows that the immune memory for HBsAg persists beyond the time at which anti-HBs disappears, conferring long-term protection.
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Introduction
Hepatitis B virus (HBV) is a leading cause of acute and chronic
hepatitis, including cirrhosis and hepatocellular carcinoma. This
serious and potentially fatal infection can be prevented by
vaccination, and a substantial reduction of new HBV infections,
carrier rate and HB-related mortality has been observed in
countries where vaccination has been implemented [1–3].
In Italy, universal vaccination of infants and 12-year-old
adolescents became mandatory in 1991 [4,5]. At the end of
2003, the ﬁrst infant cohort vaccinated in 1991 turned
12 years of age. In 2004, the vaccination of 12-year-olds was
stopped, whereas vaccination of infants continued. Over 95%
vaccination coverage was achieved in a few years with an
outstanding record of safety and effectiveness [6]. To date,
over 19 million young people under 32 years of age have been
vaccinated. Our vaccination campaign has greatly contributed
to the decline in incidence of both acute hepatitis B and acute
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infection by hepatitis Delta virus (HDV), as a consequence of
the biological association between HBV and HDV [7,8].
Although the highly protective efﬁcacy of hepatitis B vaccine
has been conﬁrmed, the long-term duration of protection
achieved by vaccination remains unclear [9]. Studies on
long-term protection induced by hepatitis B vaccination have
been mainly conducted in areas of high HBV endemicity. Some
studies suggest that vaccine-induced immunity may persist for
up to 20 years or longer, after complete primary hepatitis B
vaccination [10–14]. Other studies suggest that the immune
memory may begin to wane during the second decade after
vaccination [15–19]. Moreover, long-term follow-up data are
scarce in areas of low endemicity [20–24]. Thus, assessing the
persistence of immunity following primary vaccination in
infants and adolescents is crucial to determine whether a
booster vaccination is needed later in life, when subjects may
be at increased risk of HBV infection either due to lifestyle or
professional exposure.
In 2003, a large multicentre study was carried out in Italy to
assess hepatitis B vaccine-induced immune memory in children
who were immunized as infants 10 years earlier. Despite the
loss of protective concentrations (≥10 mIU/mL) of antibodies
to hepatitis B surface antigen (anti-HBs) in a number of
vaccinees, a strong immune memory still persisted 10 years
after primary immunization, thus suggesting that no routine
booster doses of vaccine were necessary for a decade [22]. In
2010, we decided to extend the follow-up of that study by
recalling the children, now teenagers, with the aim of assessing
the persistence of anti-HBs and immune memory 17 years
after primary vaccination.
Materials and Methods
Study participants
A cohort of vaccinees immunized as infants with three
paediatric doses of recombinant hepatitis B vaccine (Engerix
B, SmithKline Beecham, Biological, Rixensart, Belgium) given at
3, 5 and 11 months of age was ﬁrst followed-up in 2003 or
10 years after primary vaccination [22], and recalled in 2010 or
17 years after priming. At enrollment, all participants were in
good health and none had a history or presented signs or
symptoms of clinically overt hepatitis. Exclusion criteria also
included congenital or acquired immune disorder, sensitivity or
allergy to any component of the study vaccine and having
received extra doses of hepatitis B vaccine between 2003 and
2010.
Participants were subdivided into two groups: group A who
were given a booster dose of hepatitis B vaccine in 2003 and
group B who were not boosted at that time.
Ethics
The study was approved by the Ethics Committee of the
University of Milan. Before inclusion, written informed consent
was obtained from each participant or, for those still under age
(<18 years), from their parents or legal guardians.
Procedures and deﬁnitions
Participants were tested for anti-HBs concentrations and the
presence of antibody to core antigen (anti-HBc) as a marker of
HBV infection. Individuals positive for anti-HBc were tested
further for hepatitis B surface antigen (HBsAg) and HBV-DNA,
following the same laboratory algorithm applied in the 2003
study [22].
Individuals with anti-HBs concentrations ≥10 mIU/mL were
considered protected while those with antibody <10 mIU/mL
were given a booster adult dose of recombinant hepatitis B
vaccine (Engerix B, 20 lg) and retested 2 weeks later.
An anamnestic response was deﬁned as a four-fold
post-booster rise in anti-HBs concentration compared with
the pre-booster concentration or an increase up to ≥10 mIU/
mL for those who had no detectable anti-HBs.
Individuals showing post-booster anti-HBs concentrations
<10 mIU/mL were offered two additional vaccine doses at 1
and 6 months after the booster, and retested 1 month after
the third dose.
A natural booster (exposure to HBV without infection)
was deﬁned as seroconversion to ≥10 mIU/mL or at least a
four-fold increase in anti-HBs concentration in the sample
collected in 2010 versus the sample collected in 2003 in the
same subject, without revaccination and no appearance of
anti-HBc antibody. To avoid differences due to the use of
different kit batches, measurements of antibody concentra-
tions in such samples were repeated in parallel on the same
run.
Serological testing
HBsAg, anti-HBc and anti-HBs were detected by commercially
available kits (AxSYM HBsAg, CORE and AUSAB, Abbott Park,
IL, USA). The measurement range of AxSYM AUSAB was 2–
1000 mIU/mL, deﬁned by the detection limit and the maximum
of the calibration curve. Samples with anti-HBs ≥1000 mIU/mL
were diluted with the manual dilution protocol, according to
the manufacturer’s instructions, to obtain the ﬁnal sample
concentration. Samples below the detection limit (2 mIU/mL)
of the assays were recorded as undetectable. HBV-DNA was
detected by real-time PCR by the TaqMan HBV test (Roche,
Branchburg, NJ, USA) with a 95% detection limit of 6.7 IU/mL
(approximately 39 copies per mL).
All samples collected in 2003 were stored at 80°C and
thawed in 2010 for this follow-up study.
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Statistical analysis
Anti-HBs geometric mean concentrations (GMCs) were
compared between participants of group A and group B
before and after booster given in 2010 using the non-para-
metric Mann–Whitney U-test. In the case of undetectable
anti-HBs antibody concentration, an arbitrary value of
0.5 mIU/mL was assigned to allow for calculation of GMCs.
Differences in frequency were tested by the chi-square test or
Fisher exact test, when necessary. A p value <0.05 was
considered to be statistically signiﬁcant; 95% conﬁdence
intervals (95% CI) for GMCs and frequencies were also
calculated, when appropriate. Statistical calculations were
conducted using Stata Statistical Software, version 11 (Stata
Corporation, College Station, TX, USA).
Results
Features of participants
Of the 1212 eligible individuals, 571 (47.1%) were recruited. Of
these, 296 (51.8%) were female and 275 (48.2%) were male.
The median age at enrollment was 17 (range, 15.5–18.3) years;
a median of 16.7 (range, 14.8–18.1) years had elapsed since the
last dose of primary vaccination. The enrolled individuals did
not signiﬁcantly differ from those who refused their partici-
pation or were untraceable in terms of gender and year of
primary vaccination. Of the 571 recruited individuals (Fig. 1),
199 belonged to group A, who were given a booster dose of
hepatitis B vaccine in 2003 on account of anti-HBs <10 mIU/
mL, and 372 to group B, who were not boosted either because
they had antibody ≥10 mIU/mL (n = 344) or because they
refused booster despite antibody concentrations below
10 mIU/mL (n = 28).
Serological data at recruitment
In 2010 (Table 1), 416 (72.9%) teenagers had anti-HBs
≥10 mIU/mL, while the remaining 155 (27.1%) had antibody
that was <10 mIU/mL (n = 95) or undetectable (n = 60). The
proportion of individuals with seroprotective anti-HBs levels
was lower in group A than in group B (67.3% vs. 75.8%; p 0.03),
while GMC was similar in both groups (27.7 vs. 29.4 mIU/mL;
p 0.759). This was despite the fact that in 2003, as a
consequence of the booster effect, the GMC was signiﬁcantly
higher in group A than in group B (486.0 vs. 72.1 mIU/mL;
p < 0.001). Thus between 2003 and 2010, the antibody
concentration decay was much higher in group A than in group
B (from 486.0 to 27.7 mIU/mL and from 72.1 to 29.4 mIU/mL,
or 17.5 vs. 2.5-fold reduction, respectively; p < 0.001).
No subject was found to be anti-HBc positive. Fifteen
vaccinees of group B, including ﬁve with anti-HBs ≥10 mIU/mL
and 10 with anti-HBs that was <10 mIU/mL (n = 7) or
undetectable (n = 3) in 2003, showed an antibody serocon-
version to over 10 mIU/mL or at least a four-fold increase in
anti-HBs concentrations in 2010, probably due to a natural
booster response. All these subjects tested negative for
anti-HBc, HBsAg and HBV-DNA.
Anamnestic response to booster given in 2010
A total of 96 out of 155 individuals (61.9%) who had anti-HBs
concentrations that were <10 mIU/mL (n = 61) or undetect-
able (n = 35) at enrollment in 2010 accepted the administra-
tion of a booster dose of vaccine. Of these, 37 belonged to the
65 (56.9%) individuals of group A and 59 to the 90 (65.5%)
individuals of group B (Fig. 1).
Two weeks after booster (Table 2), all individuals of group
A and all but two of group B showed an anamnestic increase in
anti-HBs concentration that exceeded the seroprotective
threshold, GMC being signiﬁcantly higher in group B than in
group A (895.6 vs. 492.2 mIU/mL; p 0.039). In particular,
anti-HBs concentrations rose to over 1000 mIU/mL in 45.8%
of individuals in group B versus 32.4% in group A (p 0.196). It is
noteworthy that the antibody GMC achieved by all vaccinees
(group A plus group B) after booster was higher among those
whose pre-booster anti-HBs was <10 mIU/mL but detectable
than among those with undetectable pre-booster antibody
(1201.6 vs. 285.0 mIU/mL, p <0.001; data not shown).
Among vaccinees who had anti-HBs <10 mIU/mL in 2003,
the rate of anamnestic response and GMCs achieved after the
booster given in 2010 did not signiﬁcantly differ between those
who had already been boosted in 2003 (n = 37) and those
(n = 14) who had refused the booster (100% vs. 85.7%, p
0.073; 492.2 vs. 214.6 mIU/mL, p 0.473; Table 3).
No adverse events related to the booster dose were
reported. Finally, the two vaccinees who did not show an
anamnestic response after boosting and received two addi-
tional doses of vaccine showed an antibody response 1 month
after the third dose of vaccine with concentrations between
100 and 1000 mIU/mL in one case and >1000 mIU/mL in the
other (Fig. 1). These two individuals refused booster vaccina-
tion in 2003 despite having anti-HBs below 10 mIU/mL and
this resulted in antibody being undetectable at testing
performed at enrollment in 2010.
Discussion
In 2010, we assessed the persistence of anti-HBs antibody and
immune memory in a cohort of 571 teenagers vaccinated
against hepatitis B as infants, 17 years earlier. Of these, 199
(group A) had a booster dose of hepatitis B vaccine in 2003,
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TABLE 1. Anti-HBs concentrations (mIU/mL) in 571 participants tested in 2010 or 17 years after primary vaccination, according
to whether they were boosted (group A) or not (group B) in 2003
Vaccinees
Anti-HBs concentration (mIU/mL)
Undetectable <10 10–100 >100–1000 >1000 Subtotal ≥10 GMC (95% CI)
Group A (n = 199) 36 (18.1)e 29 (14.6) 74 (37.2) 45 (22.6) 15 (7.5) 134 (67.3)a 27.7b (19.5–39.2)
Group B
≥10 mIU/mL (n = 344) 8 (2.3) 64 (18.6) 195 (56.7) 71 (20.6) 6 (1.7) 272 (79.1)c 34.1d (29.1–40.0)
<10 mIU/mL (n = 28) 16 (57.1) 2 (7.1) 3 (10.7) 6 (21.4) 1 (3.6) 10 (35.7)c 4.8d (15–15.1)
Subtotal (n = 372) 24 (6.5) 66 (17.7) 198 (53.2) 77 (20.7) 7 (1.9) 282 (75.8)a 29.4b(24.7–35.1)
Total (n = 571) 60 (10.5) 95 (16.6) 272 (47.6) 122 (21.4) 22 (3.9) 416 (72.9) 28.8 (24.4–34.0)
ap 0.03; bp 0.759; cp <0.001; dp <0.001.
eData are numbers (%).
1212 children 
enrolled in 2003
571 
included in the study
in 2010
Group A
199/571 (34.8%)
boosted in 2003
Group B
372/571 (65.2%)
unboosted in 2003
65
<10 mIU/mL
134
≥10 mIU/mL
90
<10 mIU/mL
282
≥10 mIU/mL
37
boosted
37
≥10 mIU/mL
59
boosted
2
<10 mIU/mL
57
≥10 mIU/mL
2
two 
additional  doses
641 declined participation 
or untraceable
28 declined 
participation
31 declined 
participation
2
≥10 mIU/mL 
1 m after 3rddoseFIG. 1. Study proﬁle.
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while 372 (group B) were not boosted. Taken together, 72.9%
of vaccinees still had protective levels of antibody when tested
in 2010. The proportion of vaccinees who maintained anti-HBs
levels ≥10 mIU/mL was higher in group B than in group A
(75.8% vs. 67.3%). It is noteworthy that GMC showed a
greater reduction between 2003 and 2010 in the boosted
group than in the unboosted group (17.5 vs. 2.5-fold reduc-
tion). This suggests that the kinetics of anti-HBs decay and,
consequently, the persistence of antibody over time mainly
depend on the magnitude of the peak antibody level achieved
after primary immunization rather than on the peak reached
following booster administration, but other factors such as
genetic factors and body mass index related to the individual
may have played a role. A rapid fall in post-booster antibody
levels was also reported by an Alaskan study showing that only
41% of vaccinees maintained antibody ≥10 mIU/mL 1 year
after booster administration [12]. Similar ﬁndings were found
in mentally retarded patients as well as in healthcare workers,
who experienced a sharp drop in antibody GMC in the ﬁrst
post-booster year [25,26]. Thus, this antibody decline strongly
suggests that post-booster anti-HBs concentrations tend to
wane rapidly and eventually return to the levels detected
before the booster dose.
In this study, regarding the proportion of individuals who
maintain protective anti-HBs levels over time, we can infer that
the 199 vaccinees who had pre-booster antibody <10 mIU/mL
in 2003 would still be below the level of 10 mIU/mL in 2010, if
unboosted. Thus, adding these 199 vaccinees to those (n = 90)
who lost antibody between 2003 and 2010, we can assume
that 289 out of 571 vaccinees (50.6%) were expected to have
antibody concentrations <10 mIU/mL, 17 years after primary
vaccination as infants.
Natural booster responses were found in 15 (2.6%)
vaccinees. The fact that 10 of these vaccinees, despite having
anti-HBs below protective levels (seven with anti-HBs
<10 mIU/mL and three with undetectable antibody), showed
a strong anamnestic response in the absence of serological
signs of HBV breakthrough infections, suggests that cellular
immunity lasts much longer than humoral immunity. Similar
ﬁndings were reported in Alaska and in the Czech Republic,
where 8.2% of 1530 vaccinees followed for 10 years after
immunization and 6% of vaccinated children born to
HBsAg-positive mothers had a natural booster response
[26,27]. In Thailand, natural booster responses were observed
between 10 and 20 years after the start of primary vaccination
of children born to HBsAg carrier mothers [28,29].
Overall, the booster dose of vaccine given in 2010 elicited a
strong anamnestic response in 98% of vaccinees. The increase
in anti-HBs concentrations was higher in those with pre-boost-
ing anti-HBs <10 mIU/mL than in those with undetectable
antibody before boosting. This ﬁnding indicates that although
anti-HBs concentrations decrease over time to levels of
antibody that are <10 mIU/mL or even undetectable, a strong
immune memory still persists. This is consistent with the
outcome of long-term studies carried out in high endemicity
countries [9–13], although very recent studies [14–18] show
increased failure to respond to a booster dose of vaccine, two
decades after primary vaccination. Surveillance and additional
long-term follow-up of vaccinated cohorts are needed to
clarify this issue.
Finally, two vaccinees who did not show an anamnestic
response after boosting developed protective antibody levels
after an additional full course of vaccination. The fact that both
of these vaccinees had anti-HBs <10 mIU/mL in 2003, which
became undetectable in 2010, suggests that they were likely to
be hyporesponsive to the primary vaccination and that the
ability to respond to a booster might wane over time,
TABLE 2. Anti-HBs concentrations 2 weeks after booster vaccination given in 2010 in group A and group B
Vaccinees
Post-booster anti-HBs concentrations (mIU/mL)
Undetectable <10 10–100 >100–1000 >1000 Subtotal ≥10 GMC (95% CI)
Group A (n = 37) – – 4 (10.8)c 21 (56.8) 12 (32.4)a 37 (100) 492.2b (323.2–749)
Group B (n = 59) 1 (1.7) 1 (1.7) 3 (5.1) 27 (45.8) 27 (45.8)a 57 (96.6) 895.6b (531.4–1509.5)
Total (n = 96) 1 (1.0) 1 (1.0) 7 (7.3) 48 (50) 39 (40.6) 94 (97.9) 711.1 (496.6–1018.2)
ap 0.196; bp 0.039.
cData are numbers (%).
TABLE 3. Proportion of anamnestic response to a booster
vaccination given in 2010 in 96 individuals belonging to group
A or B according to the anti-HBs concentrations detected at
enrollment in 2003.
Anti-HBs at
enrollment in 2003
Post-booster anti-HBs
concentration in 2010
≥10 mIU/mL GMC (95% CI)
Group A
(n = 37)
<10 mIU/mL 37 (100)c 492.2b (323.2–749)
Group B
(n = 59)
<10 mIU/mL (n = 14) 12 (85.7)a 214.6b (45.8–1005.3)
≥10 mIU/mL (n = 45) 45 (100)a 1396.8 (883.5–2208.3)
ap 0.073; bp 0.473.
cData are numbers (%).
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especially in individuals with low post-priming antibody levels.
However, the small number of vaccinees examined with this
proﬁle does not allow deﬁnitive conclusions.
A limitation of this study is that the administration of a
booster dose to those with anti-HBs <10 mIU/mL 10 years
after vaccination may have somehow overestimated the
persistence of vaccine-induced immunity at 17 years after
primary vaccination.
Despite this, our study clearly shows that the immune
memory for HBsAg persists beyond the time at which anti-HBs
disappears, conferring long-term protection.
A concentration of anti-HBs ≥10 mIU/mL measured after a
primary course of vaccination is universally considered
protective, but it is questionable whether this threshold can
be periodically used for the evaluation of long-term protection,
because the drop in antibody below this value does not
necessarily mean susceptibility to HBV infection. Actually,
most vaccinees with such a serological proﬁle show a rapid and
vigorous anamnestic response when boosted.
In conclusion, our ﬁnding indicates that the immune
memory for HBsAg achieved by primary immunization with
three paediatric doses of recombinant hepatitis B vaccine given
in the ﬁrst year of life lasts for at least 17 years and additional
booster doses are not needed at this time to maintain
long-term protection. However, surveillance of vaccinated
cohorts should continue.
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